Latest Headlines

Latest Headlines

Dermira pockets $51M to bankroll skin treatments

Well-funded biotech Dermira has landed a $51 million C round to support its late-stage dermatology pipeline, rallying some high-profile investors as it dials up R&D spending and builds out its management team.

Valeant offloads aesthetic treatments to Nestlé's derm unit in $1.4B deal

Valeant CEO J. Michael Pearson is an aggressive buyer, especially when it comes to the fast-growing skincare field. But Pearson was also a seller Wednesday, shipping off rights to a handful of cosmetic products to Nestlé as the Swiss food group looks to expand into the dermatology space.

Meet RestorGenex, a biotech mosaic from Celgene founder Barer

Nearly three years removed from his Celgene retirement, Sol Barer is working to get another biotech off the ground, piecing together four drugmakers into a whole called RestorGenex and setting out to make a difference in dermatology, ocular diseases and women's health.

Nestlé plans to use its global marketing juju to rev up Galderma

Nestlé has caught the dermatology fever sweeping through Big Pharma, as companies key in on the specialty sector's growth potential. But success for Galderma, its recent skincare pickup, will depend on the global food giant's marketing power as it pushes further into the healthcare sector.

Valeant adds to skin-care quiver with $475M PreCision Dermatology buy

Valeant Pharmaceuticals has snapped up another dermatology specialist in its ongoing quest to build its business in the field. This time, it's PreCision Dermatology, a Cumberland, RI-based maker of prescription skin remedies and skin-care products sold by physicians.

NeXeption raises $21.5M to launch dermatology startup Alexar

Biotech management company NeXeption has locked in $21.5 million in a Series A round of financing to form Alexar Therapeutics, a company with a focus on treating skin disorders called inflammatory cutaneous disorders.

Almirall eyes growth in U.S., dermatology with $400M Aqua Pharma buyout

Spanish drugmaker Almirall is extending its global sales reach by picking up U.S.-based Aqua Pharmaceuticals for up to $400 million. The deal bolsters Almirall's presence in the red-hot dermatology field to boot.

Merz swoops into Obagi deal with $385M bid, topping Valeant

Drugmakers have been wooing small players in the skin-treatment field, and just last month, Valeant Pharmaceuticals announced that it had agreed to buy Obagi Medical for $345 million. But now, Merz Pharma has trumped that bid.

Valeant nabs skin-care specialist Obagi for $344M

Valeant Pharmaceuticals is socking another $350 million or so into the dermatology business. It's picking up the skin-care company Obagi Medical Products for $344 million in a $19.75-per-share buyout--just a few months after closing its $2.6 billion deal for Medicis Pharmaceutical.

Cosmetics group leads $7M round for dermatology upstart Brickell

Miami-based Brickell Biotech grabbed $7 million in a new venture round led by a South Korean cosmetics company to back its work on new chemical entities for dermatology.